Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Risk Assessment generated by a regulatory process
(RA)
last updated: 12 Jun 2014
Uso del producto INNOVAX ND SB, vacuna aviar para la enfermedad de Marek y la enfermedad de Newcastle serotipos 2 y 3 virus vivo, vector vivo de la enfermedad de Marek.
ES
-
Competent National Authority:Instituto Colombiano Agropecuario ICA ()Avenida Carrera 20 # 83-20, edificio NeoPoint 83Bogotá, Bogotá D.C.
110221, ColombiaPhone: (+57)-601-794-4492,Fax:Website: http://www.ica.gov.co,
-
Person:Sr MARTIN EMILIO RODRIGUEZ MOSQUERAPROFESIONAL ESPECIALIZADO,CRA 41 #17-81 ZONA INDUSTRIAL PUENTE ARANDA.BOGOTA, CUNDINAMARCA
, ColombiaPhone: 0571-3323700 EXT 1366 1361,Fax: 0571-3323700,Email: martin.rodriguez@ica.gov.co,Website:Related OrganizationINSTITUTO COLOMBIANO AGROPECUARIO ICA (ICA)Government agency (National/Federal)CRA 41 #17-81 ZONA INDUSTRIAL PUENTE ARANDA.BOGOTA, CUNDINAMARCA
, ColombiaPhone: 0571-3323700 EXT 1366 1361,Fax: 0571-3323700,Email: martin.rodriguez@ica.gov.co,Website:
-
INNOVAX® ND Vaccine| Intervet do Brasil Veterinária Ltda(INTERVET) | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
- Res 1250 de 2010 INNOVAX ND SB.pdf [ Spanish ]
EN
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | Risk assessment | 1 | |
